Elixir Associates reposted this
Bambusa Therapeutics Inc. has just announced the successful closing of its Seed financing round, raising $15 million to accelerate the development of innovative bispecific antibodies for immunology and inflammatory disorders. Founded by a team of industry experts, Bambusa leverages validated targets to create bispecific antibody therapeutics through innovative antibody engineering. This new funding, co-led by BVF Partners L.P. and Dawn Biopharma, and supported by Salvia GmbH and INCE Capital, will expedite the development of Bambusa's promising pipeline to Phase I clinical studies. CEO and Co-Founder Dr. Shanshan Xu Xu mentioned, "Since our inception, we have built a diverse portfolio of molecules and are uniquely positioned to make significant contributions to patients suffering from debilitating and chronic inflammatory conditions." Helmut Jeggle, Managing Director of Salvia GmbH, added, "We are thrilled to have the support of such distinguished investors. This funding will allow us to strengthen the team and advance our lead candidates through preclinical development and position us for success in clinical studies." #Biotech #Immunology #Inflammation #RaisingCapital #Seedfunding #AntibodyTherapeutics #ElixirAssociates
